CureVac Enlists Bayer To Secure Place Among COVID-19 Vaccines ‘Second Wave’
Company Faces Competition From J&J, Novavax
While demand for COVID-19 vaccines will be huge for the next two years, only those players with major manufacturing and commercial infrastructures in place will play a big role.
You may also be interested in...
The US biotech has booked orders of nearly 500 million doses for its COVID-19 vaccine, and a leaked price list from Europe shows it has secured a premium price ahead of all its rivals, including Pfizer/BioNTech.
Key cancer asset is still looking for a Phase III validation after failing to outperform Keytruda in challenging frontline NSCLC setting.
Companies claim their technologies provide more precise editing as they raise funds, but CRISPR companies remain in the lead.